For the treatment of BRAF-mutated melanoma, various combination therapy regimens of a BRAF inhibitor plus MEK inhibitor, such as vemurafenib plus cobimetinib, encorafenib plus binimetinib, and dabrafenib plus trametinib, have been approved [31]. This evidence concerns the gene MAP2K7 and melanoma.